2004 Publications

Barnham KJ, Masters CL, and Bush AI (2004) Neurodegenerative diseases and oxidative stress. Nat Rev Drug Discov. 3: 205-214.


Buckley ST, and Dodd PR. 2004) GABAA receptor β subunit mRNA expression in the human alcoholic brain. Neurochem Int. 45: 1011-1020.


Cai Z, Blumbergs PC, Koblar SA, Cash K, Manavis J, Ghabriel MN, and Thompson PD. (2004) Peripheral nervous system and central nervous system pathology in rapidly progressive lower motor neuron syndrome with immunoglobulin M anti-GM1 ganglioside antibody. J Peripher Nerv Syst. 9: 79-91.


Cooper WA, Shingde M, Lee VK, Allan RS, Wills EJ, and Harper C. (2004) "Rhabdoid meningioma" lacking malignant features. Report of two cases. Clinical neuropathology. 23: 16-20.


Culvenor JG, Ilaya NT, Ryan MT, Canterford L, Hoke DE, Williamson NA, McLean CA, Masters CL, and Evin G. (2004) Characterization of presenilin complexes from mouse and human brain using Blue Native gel electrophoresis reveals high expression in embryonic brain and minimal change in complex mobility with pathogenic presenilin mutations. Eur J Biochem. 271: 375-385.


Dean B. (2004) M1 receptor agonism, a possible treatment for cognitive deficits in schizophrenia. Neuropsychopharmacology. 29: 1583-1584.


Dean B. (2004) The neurobiology of bipolar disorder: findings using human postmortem central nervous system tissue. Aust N Z J Psychiatry. 38: 135-140.


Dean B. (2004) Role of muscarinic receptors in the pathology of schizophrenia. Am J Med Genet B Neuropsychiatr Genet. 126B: 8-9.


Dean B, Gray L, Keriakous D, and Scarr E. (2004) A comparison of M1 and M4 muscarinic receptors in the thalamus from control subjects and subjects with schizophrenia. Thalamus & Related Systems. 2: 287-295.


Dean B, Pavey G, Scarr E, Goeringer K, and Copolov DL (2004) Measurement of dopamine D2 like receptors in postmortem CNS and pituitary: differential regional changes in schizophrenia. Life Sci. 74: 3115-3131.


Dean B, and Scarr E. (2004) Antipsychotic drugs: evolving mechanisms of action with improved therapeutic benefits. Curr Drug Targets CNS Neurol Disord. 3: 217-225.


Dixon G, Garrick T, Whiteman I, Sarris M, Sithamparanathan S, and Harper CG. (2004) Characterization of GABAergic neurons within the human medial mamillary nucleus. Neuroscience. 127: 365-372.


Dixon G, and Harper CG. (2004) No evidence for selective GABAergic interneuron deficits in the anterior thalamic complex of patients with schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry. 28: 1045-1051.


Dodd PR, Foley PF, Buckley ST, Eckert AL, and Innes DJ. (2004) Genes and gene expression in the brain of the alcoholic. Addict Behav. 29: 1295-1309.


Foley PF, Loh EW, Innes DJ, Williams SM, Tannenberg AE, Harper CG, and Dodd PR. (2004) Association studies of neurotransmitter gene polymorphisms in alcoholic Caucasians. Ann N Y Acad Sci. 1025: 39-46.


George AJ, Holsinger RM, McLean CA, Laughton KM, Beyreuther K, Evin G, Masters CL, and Li QX. (2004) APP intracellular domain is increased and soluble Aβ is reduced with diet-induced hypercholesterolemia in a transgenic mouse model of Alzheimer disease. Neurobiol Dis. 16: 124-132.


Holsinger RM, McLean CA, Collins SJ, Masters CL, and Evin G. (2004) Increased β-Secretase activity in cerebrospinal fluid of Alzheimer's disease subjects. Ann Neurol. 55: 898-899.


Hynd MR, Scott HL, and Dodd PR. (2004) Differential expression of N-methyl-D-aspartate receptor NR2 isoforms in Alzheimer's disease. J Neurochem. 90: 913-919.


Hynd MR, Scott HL, and Dodd PR. (2004) Selective loss of NMDA receptor NR1 subunit isoforms in Alzheimer's disease. J Neurochem. 89: 240-247.


Hynd MR, Scott HL, and Dodd PR. (2004) Glutamate-mediated excitotoxicity and neurodegeneration in Alzheimer's disease. Neurochem Int. 45: 583-595.


Iwazaki T, Shibata I, Niwa S, and Matsumoto I. (2004) Selective reduction of chromogranin A-like immunoreactivities in the prefrontal cortex of schizophrenic subjects: a postmortem study. Neurosci Lett. 367: 293-297.


Lewohl JM, Van Dyk DD, Craft GE, Innes DJ, Mayfield RD, Cobon G, Harris RA, and Dodd PR. (2004) The application of proteomics to the human alcoholic brain. Ann N Y Acad Sci. 1025: 14-26.


Lindersson E, Beedholm R, Hojrup P, Moos T, Gai W, Hendil KB, and Jensen PH. (2004) Proteasomal inhibition by α-synuclein filaments and oligomers. The Journal of biological chemistry. 279: 12924-12934.


Liu J, Lewohl JM, Dodd PR, Randall PK, Harris RA, and Mayfield RD. (2004) Gene expression profiling of individual cases reveals consistent transcriptional changes in alcoholic human brain. J Neurochem. 90: 1050-1058.


Lowe R, Pountney DL, Jensen PH, Gai WP, and Voelcker NH. (2004) Calcium(II) selectively induces α-synuclein annular oligomers via interaction with the C-terminal domain. Protein Sci. 13: 3245-3252.


Nadri C, Dean B, Scarr E, and Agam G. (2004) GSK-3 parameters in postmortem frontal cortex and hippocampus of schizophrenic patients. Schizophr Res. 71: 377-382.


Pfefferbaum A, Sullivan EV, Adalsteinsson E, Garrick T, and Harper C. (2004) Postmortem MR imaging of formalin-fixed human brain. Neuroimage. 21: 1585-1595


Poljak A, McLean CA, Sachdev P, Brodaty H, and Smythe GA. (2004) Quantification of hemorphins in Alzheimer's disease brains. J Neurosci Res. 75: 704-714.


Ritchie CW, Bush AI, and Masters CL. (2004) Metal-protein attenuating compounds and Alzheimer's disease. Expert Opin Investig Drugs. 13: 1585-1592.


Scarr E, Pavey G, Copolov D, and Dean B. (2004) Hippocampal 5-hydroxytryptamine receptors: abnormalities in postmortem brain from schizophrenic subjects. Schizophr Res. 71: 383-392.


Smith MJ, Sharples RA, Evin G, McLean CA, Dean B, Pavey G, Fantino E, Cotton RG, Imaizumi K, Masters CL, Cappai R, and Culvenor JG. (2004) Expression of truncated presenilin 2 splice variant in Alzheimer's disease, bipolar disorder, and schizophrenia brain cortex. Brain Res Mol Brain Res. 127: 128-135.


Tannenberg RK, Scott HL, Westphalen RI, and Dodd PR. (2004) The identification and characterization of excitotoxic nerve-endings in Alzheimer disease. Curr Alzheimer Res. 1: 11-25.


Thompson KA, Churchill MJ, Gorry PR, Sterjovski J, Oelrichs RB, Wesselingh SL, and McLean CA. (2004) Astrocyte specific viral strains in HIV dementia. Ann Neurol. 56: 873-877.


Thyagarajan D, Chataway T, Li R, Gai WP, and Brenner M. (2004) Dominantly-inherited adult-onset leukodystrophy with palatal tremor caused by a mutation in the glial fibrillary acidic protein gene. Mov Disord. 19: 1244-1248.


van den Bos M, Marotta R, Goldup S, Chataway T, Firgaira F, and Thyagarajan D. (2004) Writer's cramp in an Australian pedigree with DYT1 dystonia. J Clin Neurosci. 11: 537-539.


Verdile G, Gnjec A, Miklossy J, Fonte J, Veurink G, Bates K, Kakulas B, Mehta PD, Milward EA, Tan N, Lareu R, Lim D, Dharmarajan A, and Martins RN. (2004) Protein markers for Alzheimer disease in the frontal cortex and cerebellum. Neurology. 63: 1385-1392.


Walton JR. (2004) A bright field/fluorescent stain for aluminum: its specificity, validation, and staining characteristics. Biotech Histochem. 79: 169-176.


Xue J, Tsang CW, Gai WP, Malladi CS, Trimble WS, Rostas JA, and Robinson PJ. (2004) Septin 3 (G-septin) is a developmentally regulated phosphoprotein enriched in presynaptic nerve terminals. J Neurochem. 91: 579-590.


Zavitsanou K, Garrick T, and Huang XF. (2004) Selective antagonist [3H]SR141716A binding to cannabinoid CB1 receptors is increased in the anterior cingulate cortex in schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry. 28: 355-360.


BOOK CHAPTERS


Dean B, and Scarr E (2004). Understanding the pathology of affective disorders: The contribution of post mortem brain studies. In: Affective & Mood Disorders. Ed. Joyce P. and Mitchell P. University of Sydney. Sydney.

Sundram S, Dean B, Copolov DL (2004). The endogenous cannabis system and schizophrenia. In: Castle, DJ, Murray, RM (eds) Marijuana and Madness: Psychiatry and Neurobiology. Cambridge University Press. pp 127-141.